Browsing by keyword "hydroxychloroquine"

Now showing items 1-3 of 3

    • COVID-19 and Severe Acute Respiratory Infection
      Hatch, Steven C. (2020-04-02)
      This presentation provides an overview of Severe Acute Respiratory Infection (SARI) and COVID-19, with following objectives: characterize current & near-future epidemiology of COVID-19 outbreak; provide general clinical features of SARI due to COVID; outline clinical management of COVID.

    • Searching for COVID-19 treatments: First, do no harm
      Guharoy, Roy; Krenzelok, Edward (2020-08-03)
      FDA is the gatekeeper to protect the public health and is critical to sustain US global leadership in drug innovation. Our foundation of evidence-based clinical practice is based on large, well-designed randomized controlled trials. The failure of HCQ against COVID-19 stands as prime example of the urgent need for adherence to science. Rigorous scientific objectivity Downloaded from https://academic.oup.com/ajhp/advance-article/doi/10.1093/ajhp/zxaa257/5879960 by Medical Center Library user on 17 August 2020 13 and independence must prevail in any future EUA decision by FDA. Trust in FDA’s mission to approve safe and effective medications was built over decades by the capable scientists working for the agency, and the integrity of public trust must be protected to conquer future pandemics and ensure safe use of vaccines against COVID-19 once they become available.

    • Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19
      Qaseem, Amir; Yost, Jennifer; Etxeandia-Ikobaltzeta, Itziar; Miller, Matthew C.; Abraham, George M.; Obley, Adam Jacob; Forciea, Mary Ann; Jokela, Janet A.; Humphrey, Linda L. (2020-05-13)
      Using chloroquine or hydroxychloroquine, with or without azithromycin, to prevent coronavirus disease (COVID-19) after infection with novel coronavirus (SARS-CoV-2) or to treat COVID-19 began to receive attention following preliminary reports from in vitro and human studies. While multiple studies are planned or under way, it is imperative to continually synthesize the results from the best available evidence to inform point-of-care decisions about the use of chloroquine or hydroxychloroquine. These practice points are based on a rapid and living systematic evidence review conducted by the University of Connecticut Health Outcomes, Policy, and Evidence Synthesis Group and will be updated as new evidence becomes available. The practice points development and update methods are included in the Appendix. This version of the practice points, based on an evidence review conducted on 17 April 2020, was approved by the American College of Physicians Board of Regents on 4 May 2020 and submitted to Annals of Internal Medicine on 6 May 2020.